Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia × Idarubicin × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 15 Myelodysplastic Syndromes 5 Leukemia, Biphenotypic, Acute 3 Leukemia, Myelomonocytic, Chronic 2 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Leukemia 1 Carcinoma, Hepatocellular 1

Interventions

venetoclax 15 Cyclophosphamide 13 Cytarabine 7 fludarabine 6 Azacitidine 6 ruxolitinib 5 fludarabine phosphate 5 Rituximab 5 Whole-Body Irradiation 4 Mycophenolic Acid 4 Mesna 4 Melphalan 4 Decitabine 4 revumenib 3 ibrutinib 3 Vincristine 3 Tacrolimus 3 Peripheral Blood Stem Cell Transplantation 3 Methotrexate 3 Mercaptopurine 3 Dexamethasone 3 Daunorubicin 3 Dasatinib 3 Busulfan 3 Bone Marrow Transplantation 3 quizartinib 2 ponatinib 2 pembrolizumab 2 pegaspargase 2 obinutuzumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06578247 2026-02-27

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡